TrialSignal
Clinical trial intelligence report
A Safety and Efficacy Study of Transcription Activator-like Effector Nucleases and Clustered Regularly Interspaced Short Palindromic Repeat/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT03057912-Jul 28, 2026
NCT ID
NCT03057912
Status
UNKNOWN
Phase
Phase 1
Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Executive brief
Investment-Ready Snapshot
This clinical trial, sponsored by the First Affiliated Hospital of Sun Yat-Sen University, aims to evaluate the safety and efficacy of TALEN and CRISPR/Cas9 gene editing technologies in treating HPV-related cervical intraepithelial neoplasia (CIN). Given the prevalence of HPV infections and the associated risk of cervical cancer, successful outcomes could position these gene-editing therapies as innovative treatment options in a market with significant unmet needs. The competitive landscape includes traditional HPV treatments and emerging gene therapies, necessitating thorough diligence on regulatory pathways and potential market entry strategies.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03057912
Indication
Human Papillomavirus-Related Malignant Neoplasm
Modality
protein therapy
Target
Transcription Activator-like Effector Nucleases (TALEN) and Clustered Regularly Interspaced Short Palindromic Repeat/Cas9 (CRISPR/Cas9) targeting HPV16 and HPV18 E6/E7 genes.
Intervention
TALEN, CRISPR/Cas9
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.